SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (1447)2/7/2003 4:57:04 AM
From: Icebrg  Read Replies (1) of 3158
 
>>No one ascribed any value to Remicade which is a lot bigger than Embrel, even though no one notices this fact. >>

This is due to the fact, that in a place like this, most of the interest is not directed towards a drug per se, but more to the transformation of the value of its sponsor, if its development should turn out to be successful.

I am sure that Embrel, having been swallowed by Amgen, will soon start to be perceived as un-exciting as Remicade already is.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News